BACKGROUND Adjuvant systemic chemotherapy (ASCT) in lymph node-negative breast (LN-) cancers improves survival. The majority of (LN-) patients receive ASCT when the St. Gallen criteria or its modifications are used, as accurate identifiers which patients benefit from ASCT are lacking. This may imply over-treatment in many patients. AIM To evaluate which patients or primary tumor factors predi...

PURPOSE/OBJECTIVES To present the novel Symptom Cluster Experience Profile (SCEP) framework for guiding symptom research in adult survivors of childhood cancers and other subgroups at risk for high symptom burden. DATA SOURCES Empirically derived model of symptom cluster experience profiles, existing theoretical frameworks, and data-based literature on symptoms and quality of life in adult su...

First, patients may always develop a second severe illness, even a second cancer. Second, things are not always as they are expected to be. So, careful diagnosis is mandatory. Third, morphology is very important, but sometimes misleading. Always be aware of morphological variants!

purpose: to present a case of bilateral enlargement of eyelids in 29 year old man with sclromyxedema syndrome. case report: a 29- year- old man was referred to labbafinegad clinic with bilateral enlargment of upper and lower eyelids, and foreign body sensation since 9 year ago. investigating of patients history show renal deasese(hematuria ) since 9 year ago. in systemic examination the patient...

lupus erythematosus (le) is an autoimmune disease. the mortality rate and causes of death are different in various countries. the present study is done to find out the causes of mortality in the systemic lupus erythematosus (sle) patients in lupus unit of rheumatology research center and other wards of shariati hospital. this study was retrospective according to medical records of patients who ...

Cytokines are key modulators of the immune responses and represent promising therapeutics for a variety cancers. However, successful translation cytokine-based therapy to clinic is limited by, among others, severe toxicities lack efficacy due cytokine pleiotropy off-target activation cells. Engineering cytokines with enhanced therapeutic properties has emerged as strategy overcome these challen...

Systemic therapy is one of a number of treatment options routinely used in the management of advanced, unresectable neuroendocrine tumours (NETs). In contrast to many of the other NET treatment modalities, there is at least some evidence base to justify its use. Even so, well-designed clinical trials are limited, since conducting clinical research in this complex group of rare cancers is challe...